Hodgkin lymphoma outcomes in the novel agent era, genomic safe harbors for precision T cell engineering, and a transcriptomic atlas to map imatinib resistance in CML
Blood Podcast
00:00
The Effects of Novel Agents on Outcomes and Practice Patterns
Researchers looked at a cohort of consecutive patients with relapsed or refractory classic Hodgkin lymphoma who underwent autologous transplant. Treatment approaches were quite different in the modern era of 2011 to 2020, they found. For patients transplanted in partial response, overall survival was superior in themodern era. There was a trend toward lower non-relapsed mortality in the modern Era.
Transcript
Play full episode
